Please login to the form below

Not currently logged in
Email:
Password:

GW Pharmaceuticals

This page shows the latest GW Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

The year of the blockbuster

The year of the blockbuster

Emanating from the pipelines of global pharma giants like Novartis, Johnson &Johnson and Pfizer, as well companies such as Denmark’s Novo Nordisk and Indivior and GW Pharmaceuticals, both of the ... Epidiolex from GW Pharmaceuticals:With a PDUFA date

Latest news

  • Cancer pain: opioids set to dominate Cancer pain: opioids set to dominate

    Phase III: opioid agonists. GW Pharmaceuticals has developed a buccal spray known as nabiximols or Sativex, which comprises delta-9-tetrahydrocannabinol (27mg/mL) and cannabidiol (25mg/mL), as an analgesic agent ... WEX Pharmaceuticals is conducting a

  • Almirall launches Sativex in Italy Almirall launches Sativex in Italy

    The drug, developed by GW Pharmaceuticals, was approved by Italian authorities in May and comes to the market with a reimbursed priced that GW said was “ consistent with the reimbursed … price ... Sativex has been given a rolling launch in Europe,

  • GW Pharma says German Sativex pricing GW Pharma says German Sativex pricing "unacceptable"

    GW Pharma says German Sativex pricing "unacceptable". May pull MS drug from market. ... GW Pharmaceuticals and partner Almirall have said they may pull Sativex from the market in Germany after failing to agree a price for the drug with the national

  • Almirall files cannabis-based MS drug Sativex in additional EU markets

    by GW Pharmaceuticals. ... It is manufactured by GW Pharma under Home Office licence at an undisclosed location in the UK, and represents the first new therapeutic class to treat spasticity in over 10 years.

  • Novartis gains licence for GW's Sativex

    Novartis gains licence for GW's Sativex. GW Pharmaceuticals has entered into an exclusive licence agreement for Novartis to commercialise Sativex in several key territories. ... GW Pharmaceuticals has entered into an exclusive licence agreement for

More from news
Approximately 0 fully matching, plus 43 partially matching documents found.

Latest appointments

  • GW Pharmaceuticals strengthens research and development team GW Pharmaceuticals strengthens research and development team

    GW Pharmaceuticals strengthens research and development team. Appoints Dr Volker Knappertz and Professor Ben Whalley. ... GW Pharmaceuticals has appointed Dr Volker Knappertz (pictured right) as its chief medical officer (CMO), a role that will see him

  • GW Pharmaceuticals promotes Adam George to MD GW Pharmaceuticals promotes Adam George to MD

    GW Pharmaceuticals promotes Adam George to MD. And Scott Giacobello joins as chief financial officer. ... UK biopharma company GW Pharmaceuticals has promoted chief financial officer Adam George to UK managing director.

  • GW hires Pfizer’s Kenneth Sommerville GW hires Pfizer’s Kenneth Sommerville

    GW hires Pfizer’ s Kenneth Sommerville. Appointed VP clinical research at company specialising in cannabinoids. ... Dr Kenneth Sommerville has left his role at pharma giant Pfizer to join GW Pharma.

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics